Acute Acalculous Cholecystitis Linked to Lemtrada Use in RRMS Patients, FDA Reports
News
Acute acalculous cholecystitis (AAC) is a rare but potentially life-threatening adverse effect linked to treatment with Lemtrada (alemtuzumab) in patients with relapsing-remitting multiple sclerosis (RRMS), according to ... Read more